SNSS:NASDAQ

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
SNSS:NASDAQ

Expert Comments:

Maxim Jacobs, Edison Investment Research (5/18/17)
"Sunesis lead program is SNS-062, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice a day dosing. . .a Phase Ib/II is expected to begin in H1/17."

In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program.
read more >
Maxim Jacobs, Edison Investment Research (5/10/17)
"Sunesis Pharmaceuticals Inc. announced on 1 May 2017 that it would be withdrawing its EMA marketing application following feedback from the agency, which made it clear that it was unlikely to approve vosaroxin (Qinprezo) with the current data. . .the company has refocused its efforts squarely on SNS-062, which will now be the lead development program. The non-covalent Bruton's tyrosine kinase (BTK) inhibitor has the potential to be effective in patients that become resistant to other covalent BTK inhibitors such as Imbruvica (ibrutinib; AbbVie, Janssen). . .the company has a Phase Ib/II clinical trial that will begin in Q217 in patients with confirmed C481S mutations."

Mara Goldstein, Cantor Fitzgerald (5/2/17)
"Sunesis Pharmaceuticaks Inc.'s SNS-062 may have utility as a BTK inhibitor in treated patients with C481S mutations due to its binding site. Early data in healthy volunteers have already been presented, but we think it's the Phase IB/II study in advanced B cell malignancies for patients with prior exposure to Imbruvica that's needed to generate greater value for the shares."

Jim Birchenough, Wells Fargo Securities (5/1/17)
"Sunesis Pharmaceuticals Inc. announced today its plan to withdraw the European Marketing Authorization Application for vosaroxin. . .SNSS noted that it is reducing investment in the AML program and shifting an increasing portion of resources to the kinase inhibitor pipeline, including the non-covalent reversible BTK-inhibitor SNS-062. SNSS plans to continue the development of vosaroxin through a modest investment in investigator-sponsored trials, and to assess business development alternatives to support the conduct of another pivotal trial of vosaroxin for future regulatory filing. . .we are maintaining our OUTPERFORM rating. . .we see significant upside potential on novel BTK inhibitor SNS062."

Maxim Jacobs, Edison Investment Research (4/24/17)
"Sunesis Pharmaceuticals Inc. lead program is Qinprezo, a quinolone derivative for relapsed/refractory acute myeloid leukemia without the dose limiting cardiotoxicity of anthracyclines. . .significant potential remains in Europe where Qinprezo has data comparable to those used in other approvals. . .Sunesis is also advancing its clinical asset, SNS-062, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice a day dosing . .Phase Ib/II is expected to begin in 1H17."

Maxim Jacobs, Edison Investment Research (3/23/17)
"Sunesis Pharmaceuticals Inc.'s lead program is Qinprezo, a quinolone derivative for relapsed/refractory acute myeloid leukemia (AML) without the dose limiting cardiotoxicity of anthracyclines. The FDA discouraged submitting an NDA after it missed its primary endpoint, but significant potential remains in Europe. . .a decision by CHMP is expected by mid-2017. . .SNS-062, a novel non-covalent, oral BTK inhibitor may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile. . .a Phase Ib/II is expected to begin in H117."

More Expert Comments

Experts Following This Company

Jim Birchenough – Wells Fargo Securities
Mara Goldstein, Senior Analyst – Cantor Fitzgerald
Maxim Jacobs – Edison Investment Research
Eric Schmidt – Cowen & Co.

The information provided above is from analysts, newsletters, the company and other contributors.

Sunesis Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
 
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
Sunesis Pharmaceuticals Inc. Content